Oct 12 (Reuters) – Bristol Myers Squibb said on Monday its experimental drug met the main goal of a late-stage trial in patients with idiopathic pulmonary fibrosis, a serious lung-scarring disease.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sahal Muhammed)
Brought to you by www.srnnews.com
SRN News — View the original story at SRNNews.com.
